How Can Clinical Trials Mobilize the Diversity Efforts?
Presenter:
We Recommend
Disclosures
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
- Grant Support/Research Contract - Abbott; Abiomed; Alleviant Medical; Amgen; AM-Pharma; Arena Pharmaceuticals; AstraZenca; Biosensors; Biotronik; Boston Scientific Corporation; Bristol-Myers Squibb; CardiaWave; CeloNova; Chiesi; Concept Medical; Cytsorbents; Daiichi-Sankyo/Elil Lilly and Company; Element Science; Faraday; Humacyte; Idorsia Pharmaceuticals; Janssen Pharmaceuticals; Magenta; Mediasphere; Medtelligence; Medtronic; Novartis; OrbusNeich; Penumbra; PhaseBio; Philips; Pi-Cardia; PLx Pharma; Protembis; RenalPro; RM Global; Shockwave Medical; Vivasure; Zoll; MedAlliance; MJH Healthcare; Atricure Inc
- Consultant Fee/Honoraria/Speaker’s Bureau - AstraZenca; Ionis Pharmaceuticals; J-Calc; Novartis; Novo Nordisk; Vectura; WebMD; IQVIA; McVeigh Global; Radcliffe; SL Solutions; TARSUS Cardiology; Esperion Science/Innovative Biopharma; E.R. Squibb & Sons, LLC; Boehringer Ingelheim; Lilly and Company
- Equity/Stock(s)/Options - Elixir; STEL; ControlRad (spouse)
- Scientific Advisory Board, JAMA Cardiology Associate Editor - AMA
- BOT Member, SC Member CTR Program - ACC
- Women in Innovations Committee Member - SCAI
- Faculty Members - Cardiovascular Research Foundation